third everyone. Welcome and quarter good XXXX Kaila, Thanks, conference our to call. afternoon,
for AxoGen. are to growth of report another pleased strong We quarter
independent nearly grew This improvements and consistent year, of channel. earlier expectations. Third our in in sales the stabilization XX% our direct team organization growth seeing direct After investing we’re from sales our quarter, we third million. XX%. productivity to revenue and this was significant were of revenue our $XX.X with up In saw improvements the quarter enhancements the team productivity
Our product in support now surgeon X,XXX our creating increasing With nerve the more evidence we’re our nerve evidence by a products of algorithm demonstrated with is and clinical acceptance RANGER outcomes. body of repair, portfolio. in repairs growing than clinical meaningful and growth driven for body of recovery Registry differentiated a AxoGen’s consistency in of
today U.S. diseases Therapy under aims Administration Century and Nerve announce to Medicine Graft. Avance excited regenerative medicine treatment the the Advanced The for of or serious RMAT Food for RMAT designation therapies of streamline that and development Cures Drug We’re conditions. the designation to intended Act Regenerative life-threatening granted XXst the
significant unmet continue nerve options. the need is repair of to regeneration and the technologies norms AxoGen nerve strength treat medical and the commercialization injuries. development peripheral we on and and challenge historical the specifically RANGER to improved it within of RMAT repair, intended treat, evidence that Our designation disease regenerative reverse eligible life-threatening both serious the condition needs cure the for medicine if the is or a designation has is modify, such a medical to preliminary for address or clinical indicates potential highlights unmet product or condition. or for data science Registry of will the The disease for therapy the therapy focused and to
and experience surgical competing with products. XX We techniques conduit historical have years more of than
and We field. nerve have market in defined as repair the AxoGen leader the peripheral this established
and peripheral see in building of nerve products innovator repair awareness of expanding advances with our use and early-adopter are We surgeons.
who of developing are repair We the the majority middle be towards segment are development market. the towards to moving nerve excited the adopters, –
surgeons refer us to awareness, to the educating which these pillars we growth. We advocates, initiatives We our our of market introducing believe strategic progress new quarter to plan evidence, strategic in our long-term each of clinical these of continue in market the the products and on our allow and execution as of I’ll sales building on executing to develop will of nerve growing body areas. comment repair. initiatives, and now developing sustainable expanded five our applications growth; build
Meeting, promotional market clinical which of educational First, of hand with for we is conferences meeting, surgeons At the the AxoGen repair we rapidly American surgeons. the Society hospitals, in in growing XXrd awareness by continue with to on meeting quarter, more the Surgery symposium AxoGen and hosted the nerve build our XXX Hand support clinical our which participated focused for largest an evidence products than body society of engaging attendees, the algorithm. with In Annual and of events.
The During population year-round with awareness by We products. in a recovery more options outcomes increase in and these over the motor repairs. nerve for of or featuring of of consistency stories investigators, of of upper patients from an substantial data meaningful life more RANGER gap Fraser repair nerve using update one work XXX to sensory function. and nerve through a presented peripheral review largest registry to continues our and meaningful time, repair Registry, our was Dr. variety improved our Leversedge, support whose than recovery and quality lengths damage repairs shows RANGER symposium, one on of is and highlighting to-date. the extremity XX% expanding of the This
reconstruction One mastectomy prophylactic trained ReSensation breast feel flap patients and tested with autologous performed When XX, recommended all to At positive and technique. ruptured, of she for grandmother was her breasts. plastic she gene by is cancer. maternal had the to age lived aunts the implants, a her our cancer, And three met one the of implants for engaging world in mastectomy. as Tara and own surgeon with Tara in didn’t history breast reconstructive neurotization. removal sensation implants account, implants the susceptibility she lost She normal losing years. of double of had in with she XX wasn’t surgeon with as the chose a the before reconstruction breast Tara’s a her have mother, these much of Tara. cancer by her BRCAX. and family who
result As surgery, ReSensation. her in Reconstruction including On Breast engaged tells the breast helped active Month. XX, or events fully breasts reconstruction supported she and Awareness October and Cancer in an now Awareness we is of in BRA Breast October is Tara sensation lifestyle. had awareness of These a Day. several options, participated us
participated We many Tara interactions New meaningful against just researching also those events there in X,XXX we were cancer the event in across we in the and Cancer XX patient patients strides had women Orleans, Society like participated focused making with total, options. where breast attendance. in country In actively where over American their
these to excited option We’re another for complete solution. provide who a more seeking are women
surgical nerve plan hand American surgeons. of growing Extremity months of total for the attendees to in around where a repair average, on and the concept peripheral Oral Maxillofacial a we technique recent more The during nerve program. Program, they is double Programs confidence sessions injuries growth noticed drive of surgeon excitement a We the the and in iatrogenic than included our surgeon repair, programs the total OMF on was They surgeon traffic development increase evaluation. conducted nerve Included gain evident relative referrals train and education in in XX five repair surgeons meeting events presentations and of best XXXX, and seven they and advocates. the surgeon the for we led attend significant pillar On prior repair. expect the of allow utilization national The awareness generation of on conduct including one additional education four years. microsurgery to on and quarter fellows identification of nerve adoption third Fellows next and early second procedures need Our XXXX. We surgeon repair of the from nerve Upper increasingly Conference. Association both utilization Fellows the for after to during training conduct of than both and our practices We two-thirds events see focused was Surgeons focus and breakout six to more in year. an in quarter focused scientific and during These advances increased products. for
hosted these permanent focus add nerve to numbness reconstruction. This see to for patients. challenges the lip, reconstruct on found many program OMF enrolled, function mandible function. repair opportunity mouth the sensory their have was Surgeons and untreated, an our the be patients fully in and of for into educational these We during option now patient with went the chin. nerves, these of significant injuries giving program opportunity educational to with leaving we approach with return surgical an able nerve associated also Historically, quality-of-life now provide a repair September surgery in that are standard second surgeons and of
the nerve We’re reconstructions. pleased engagement repair to and to easiness add high-level see by to their the participants
Our to grow third pillar is evidence. body clinical the of
clinical The of now both library publications products. for peer-reviewed reinforces XX. the and of AxoGen’s presentations of growing and nerve the peripheral Our body repair importance publications volume numbers evidence of
new injuries. than of and Avance nerve repairs the Nerve in has X,XXX Registry RANGER provide enrolled to Graft more evidence Our continues significant management
Society the data recovery and exceed continues and the consistently gap RANGER As RANGER to the XXX function. Hand. pivotal mentioned, meaningful than decision-making by at assist outcomes to Avance of synthetic their repairs adoption of We This Avance are sensory American continue Nerve enrollment nerve digital Registry data and in understand nerve outcomes autograft Surgeons was recently injuries to the synthetic III in with enroll. morbidities. to and without more lengths to for a platform similar better The data to anticipate Graft Phase in associated upper clinical algorithms. donor extremity are treatment site conduits comparing data nerve presented nerve studies on motor Surgery for We in our using that variety this and repair. demonstrates from associated completed the support to nerve study repair These to produce important year-end. expand support saw conduits our in of data be that continues those
to oral clinical our plastic to we’ve also build surgeons, evidence and surgery. in maxillofacial grown and continue addition the In hand reconstructive with we experience
launch. portfolio, of began become AxoGen, AxoGen’s symmetry, to We XX% associated use the Clinical patient injuries announced associated repairs the reconstruction which with recovery efficient neurotization technique, reproducible we plastic as products the believe now see restores the we’re our application application surgical with to expanded these of will in completed reconstruction ideal ReSensation complex neurotization. the we now partner end these meaningful surgeon as nerve launch and size, such XX% patients. for of neurotization AxoGen the breast the injuries technique in continue mandible multiunit potential data announce with that sensation on centers reconstructive resection. tumor the breast the As developed that to portfolio shape, pleased harvest. over can of to training the and with year. breast for We due XX expanded year, injuries by benign we last part plan incorporates the breast reconstructive and centers and confident to application develop Late reconstruction repair training of in of showed XX all these We’ve a risk surgeons. initial to at to these comorbidity softness next and autograft products iatrogenic nerve centers and we our into provide solution At without of of ReSensation surgeons XXXX, more
outcomes believe sensation of autologous registry We’re We the or in who women registry. reconstruction now demonstrate ReSensation the meaningful study women enrolling Sensation-NOW a outcomes physical choose mastectomy. life will patients recovery and from quality-of-life provides Sensation-NOW for this will following for that clinical technique data quality and sensation breast that neurotization. neurotization of outcomes in
execution. fourth Our sales is pillar
sales last to growing the we year. more several team, XX our continue four with quarters year. We we XX and mentioned, less for the quarter recent company made quarter enhancements the to direct that in sales of an see in enhance commercial than and in have the increase I our With with XX% As representatives, organizational team. expand been current ended reps of one our than
direct XX continue will our and end exceed in team sales the We reps expect of by sales XXXX. invest to to
in currently we independent U.S., In execution our force supporting agencies sales XX of addition our sales strategy. the the commercialization direct to have
of this changes During QX, we we performance following saw implemented. in a the channel stability
to Our aspect selected will in sales important agencies continue territories. an growth our of represent
the commercial XX% and is our the surgeons quarter. at revenue growing early platform to number This additional penetration the grow XXX, and up products driver active to continue repair. investments driven sales revenue our quarter, algorithms, as Nerve active key of along our make stage increased broad we of XX accounts in accounts, across just for increase of repair to of an channel active products. of nerve Most opportunities growth Nerve treatment from across XX%, XXX growth. nerve QX accounts with one will increase an and increased Nerve accounts XXXX. Avance penetration active is than expand by active in AxoGuard of the generate greater in of accounts accounts, Connector Protector increased AxoGuard our times In peripheral continue of of third of Graft, We are adoption penetration still of The ordering provide number our for the by the the an ordering account and six the
all surgeons full is algorithms across continuum treatment objective to four nerve our Our their to of to repair. include of implants continue surgical expanding the
of many products as company in in positioned repair applications to are unmet and new are solutions develop this fifth nerves needs. is space, and leading nerve Our There of pillar needs new introduction of surgical repair. expanded these peripheral the we, for a in growth the
opportunities making damage. portfolio current innovate We’re both investments peripheral well with new in for as as nerve patients to solutions our introduce
existing to portfolio. markets Analyst market Day applications are surgery, chronic today, lower needs the for surgical to associated new opportunity migraine future. opportunities prime good or for introduce recurrent urology, around of large The AxoGen pain and reconstruction for our in with potential head surgical pain. development our nerve in non-pharmacologic maxillofacial significant pain. neck to product expanded issues of area an universe repair, such suffer management and may more progress expanded hernia sources the November. at products creates surgical Millions with these work of address total in in causes nerve apply pain the this techniques effective extremity, in and repair as and about many products revenue of the opportunities management surgery, and initiatives made and the trauma, pain and potential people us expect identifying extremity to a replacement, joint neuropathy headaches, management XXXX is in upper talk our We’ve our resolution and provide offer and market The oral breast Although pain this and expanded our revenue applications
Before I over the was Pete, strong highlight again a call that AxoGen. turn to want to QX I for quarter
biologically therapy than active acceptance with of Avance surgeon Nerve clinical Our years performance reflects Graft, of growing a more nerve XX evidence.
clinical the which with significant the We of and unmet are recognizes repair evidence effective pleased existing acknowledges needs a strength RMAT the nerve designation, for solution.
of We expect accounts sales continue active representative will grow. productivity and penetration to
our strong gross strategic continue We against growth, maintaining driving execute initiatives and while XX%. revenue above to are margins
new AxoGen our professional meetings in repair successful and education at demonstrating portfolio awareness, our educational for and and interactions of core areas. are surgical awareness an programs surgeons. increasing experiencing continue on our society solutions focus nerve applying adoption and and at the portfolio We are Surgeons of applications
with surgical We are exploring neurotization, expansion reconstruction we are of OMF making management breast investments to and markets grow and in pain.
and market our sustainable driving developing for repair AxoGen. and opportunity to progress our with long-term the emerging pleased continue nerve We’re growth with
Now, turn to Pete? over Pete. call I’ll the
